Juan Blanco-Heredia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Juan Blanco-Heredia has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Edaise M. da Silva
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
15 shared publications - Jorge Sergio Reis-Filho
Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY USA
13 shared publications - Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
13 shared publications - Diana Mandelker
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY
11 shared publications - Michael F. Berger
Memorial Sloan Kettering Cancer Center
11 shared publications - Alvaro Quintanal-Villalonga
Memorial Sloan Kettering Cancer Center
10 shared publications
Latest Publications
- 3 March 2026
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (5) , 307-313
Microglandular adenosis, triple negative breast carcinoma and DNA repair defects
Aims: A subset of microglandular adenosis (MGA) displays protein expression and molecular genetic alterations similar to those of synchronous triple-negative breast carcinoma (TNBC), supporting the hypothesis that MGA is a non-obligate precursor lesion to a subset of breast carcinomas. Here, we further explore this association in the context of genomic instability. Methods: We use whole-genome sequencing to investigate the genetic landscape of two unusual cases of MGA associated with carcinoma in the setting of two distinct varieties of genomic instability. Results: The first case describes a patient with Lynch Syndrome developing a low-grade TNBC of the left breast with adenoid cystic-like and MGA-like growth patterns and a contralateral, right breast MGA. Both carcinoma and contralateral MGA showed loss of MSH2 and MSH6 proteins. Molecular studies identified somatic TP53 hotspot mutation only in carcinoma. A germline MSH2 mutation was detected in all samples, and somatic MSH2 pathogenic mutation was detected only in carcinoma components, while the contralateral MGA displayed loss-of-heterozygosity of the wild-type allele, indicating distinct mechanisms of biallelic inactivation of MSH2 between the samples. The second case consists of atypical MGA and associated high-grade TNBC arising in a setting of homologous recombination deficiency (HRD) with molecular signatures suggestive of BRCA2 -like/HRD-associated mutational features in addition to shared TP53 alterations. Conclusions: Genomic instability, either due to mismatch repair protein deficiency or due to HRD, may play a role in MGA, MGA-associated carcinogenesis and distinct morphological patterns.
- 3 March 2026
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (5) , 307-313
Microglandular adenosis, triple negative breast carcinoma and DNA repair defects
Aims: A subset of microglandular adenosis (MGA) displays protein expression and molecular genetic alterations similar to those of synchronous triple-negative breast carcinoma (TNBC), supporting the hypothesis that MGA is a non-obligate precursor lesion to a subset of breast carcinomas. Here, we further explore this association in the context of genomic instability. Methods: We use whole-genome sequencing to investigate the genetic landscape of two unusual cases of MGA associated with carcinoma in the setting of two distinct varieties of genomic instability. Results: The first case describes a patient with Lynch Syndrome developing a low-grade TNBC of the left breast with adenoid cystic-like and MGA-like growth patterns and a contralateral, right breast MGA. Both carcinoma and contralateral MGA showed loss of MSH2 and MSH6 proteins. Molecular studies identified somatic TP53 hotspot mutation only in carcinoma. A germline MSH2 mutation was detected in all samples, and somatic MSH2 pathogenic mutation was detected only in carcinoma components, while the contralateral MGA displayed loss-of-heterozygosity of the wild-type allele, indicating distinct mechanisms of biallelic inactivation of MSH2 between the samples. The second case consists of atypical MGA and associated high-grade TNBC arising in a setting of homologous recombination deficiency (HRD) with molecular signatures suggestive of BRCA2 -like/HRD-associated mutational features in addition to shared TP53 alterations. Conclusions: Genomic instability, either due to mismatch repair protein deficiency or due to HRD, may play a role in MGA, MGA-associated carcinogenesis and distinct morphological patterns.
- Open Access
- 12 December 2025
- Published by Springer Nature in Nature Genetics
- Vol. 58 (1) , 232
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
- 12 December 2025
- Published by Springer Nature in Nature Genetics
- Vol. 58 (1) , 232
Open AccessPublisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
- Open Access
- 16 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (6) , 1452-1462
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Acquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilized a clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing. Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) enzymes were prevalent and enriched in post-treatment hormone receptor-positive cancers. These signatures correlated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy in hormone receptor-positive metastatic breast cancer. Whole-genome sequencing of breast cancer models and paired primary-metastatic samples demonstrated that active APOBEC3 mutagenesis promoted therapy resistance through characteristic alterations such as RB1 loss. Evidence of APOBEC3 activity in pretreatment samples illustrated its pervasive role in breast cancer evolution. These studies reveal APOBEC3 mutagenesis to be a frequent mediator of therapy resistance in breast cancer and highlight its potential as a biomarker and target for overcoming resistance.
- 16 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (6) , 1452-1462
Open AccessAPOBEC3 mutagenesis drives therapy resistance in breast cancer
Acquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilized a clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing. Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) enzymes were prevalent and enriched in post-treatment hormone receptor-positive cancers. These signatures correlated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy in hormone receptor-positive metastatic breast cancer. Whole-genome sequencing of breast cancer models and paired primary-metastatic samples demonstrated that active APOBEC3 mutagenesis promoted therapy resistance through characteristic alterations such as RB1 loss. Evidence of APOBEC3 activity in pretreatment samples illustrated its pervasive role in breast cancer evolution. These studies reveal APOBEC3 mutagenesis to be a frequent mediator of therapy resistance in breast cancer and highlight its potential as a biomarker and target for overcoming resistance.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Outcome and treatment responses. A, Kaplan–Meier analysis of the disease-specific overall survival assessed from the time of diagnosis. B, Pie chart summarizing radiologic treatment response to platinum-based chemotherapy received in any line of therapy. C, Swimmer plot summarizing treatment modalities used and time-on-treatment, with time of pathologic samples collected and analysis performed indicated. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Outcome and treatment responses. A, Kaplan–Meier analysis of the disease-specific overall survival assessed from the time of diagnosis. B, Pie chart summarizing radiologic treatment response to platinum-based chemotherapy received in any line of therapy. C, Swimmer plot summarizing treatment modalities used and time-on-treatment, with time of pathologic samples collected and analysis performed indicated. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Mutation and CNA landscape of aSCLC. A, Mutations and CNAs in aSCLC in comparison to the control groups of sSCLC (n = 206) and pulmonary carcinoids (n = 157) analyzed by MSK-IMPACT. OncoPrint summarizing assays performed and overall genomic features: MSI vs. MSS, TMB, and genomic signature (full signature analysis shown in Supplementary Fig. S5). Case A09 lacked a matched normal DNA sample and was therefore excluded from TMB, MSI, and signature analysis. Displayed genomic alterations include selected recurrently altered genes (see Supplementary Tables S5 and S6 for a full list of detected alterations). For patients with multiple samples, the index sample is displayed (see “Methods”). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, Expression of recurrently amplified genes by IHC in two representative cases (scale bars, 100 μm) and (C) by RNA-seq in cases with available data. Arrows in C indicate cases harboring corresponding amplifications. TPM, transcripts per million; MMR, mismatch repair; N/A, not available; MSS, microsatellite stable.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Mutation and CNA landscape of aSCLC. A, Mutations and CNAs in aSCLC in comparison to the control groups of sSCLC (n = 206) and pulmonary carcinoids (n = 157) analyzed by MSK-IMPACT. OncoPrint summarizing assays performed and overall genomic features: MSI vs. MSS, TMB, and genomic signature (full signature analysis shown in Supplementary Fig. S5). Case A09 lacked a matched normal DNA sample and was therefore excluded from TMB, MSI, and signature analysis. Displayed genomic alterations include selected recurrently altered genes (see Supplementary Tables S5 and S6 for a full list of detected alterations). For patients with multiple samples, the index sample is displayed (see “Methods”). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, Expression of recurrently amplified genes by IHC in two representative cases (scale bars, 100 μm) and (C) by RNA-seq in cases with available data. Arrows in C indicate cases harboring corresponding amplifications. TPM, transcripts per million; MMR, mismatch repair; N/A, not available; MSS, microsatellite stable.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromothripsis and corresponding cancer gene amplifications and losses. A, Representative Circos plots of SVs and CNAs across the genome by WGS. Outer band shows an ideogram of chromosome positions and cytogenetic bands. Second band depicts total CN, and third band shows minor allele CN. The inner circle depicts SVs as arcs connecting the two relevant genomic points as identified by three algorithms (see “Methods”). CNAs in key cancer genes in the regions of chromothripsis (red, amplifications; blue, deletions) are displayed. Circos plots for all cases are shown in Supplementary Fig. S6. B, CN log ratio plots from the FACETS algorithm displaying the distinctive oscillating CN states on chromosomes with chromothripsis. CN segments are shown in red. Focal segments (<2 MB in size) are shown as enlarged points for visual purposes. Selected amplifications are indicated (yellow). C, Summary of chromosomal location of chromothriptic events in cases analyzed by WGS and tNGS. Also shown are selected amplifications and losses in oncogenes and tumor suppressors, respectively, localized to the chromothriptic chromosomes. Full list is provided in Supplementary Table S7. D, Schematic summary for the rate of major genomic mechanisms detected in the set analyzed by WGS (n = 11) and in the full cohort (n = 20). In the lower diagram, major chromosomes involved by chromothripsis are indicated in the inner doughnut, and corresponding recurrent gene amplifications are indicated in the outer doughnut. E, Total number of SVs identified in samples analyzed by WGS. Variants are color-coded by type. F, Number of fusions predicted in samples with available RNA-seq. G, Diagram illustrating putative enhancer hijacking in case A17 with chromothripsis on chromosome 2 resulting in translocation between SH3RF3 on chromosome 2 and upstream regulatory region of CCND1 on chromosome 11. Epigenetic landscape surrounding the breakpoint was extrapolated from data from multiple tissue types (Epilogos search tool). ChrT, chromothripsis.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromothripsis and corresponding cancer gene amplifications and losses. A, Representative Circos plots of SVs and CNAs across the genome by WGS. Outer band shows an ideogram of chromosome positions and cytogenetic bands. Second band depicts total CN, and third band shows minor allele CN. The inner circle depicts SVs as arcs connecting the two relevant genomic points as identified by three algorithms (see “Methods”). CNAs in key cancer genes in the regions of chromothripsis (red, amplifications; blue, deletions) are displayed. Circos plots for all cases are shown in Supplementary Fig. S6. B, CN log ratio plots from the FACETS algorithm displaying the distinctive oscillating CN states on chromosomes with chromothripsis. CN segments are shown in red. Focal segments (<2 MB in size) are shown as enlarged points for visual purposes. Selected amplifications are indicated (yellow). C, Summary of chromosomal location of chromothriptic events in cases analyzed by WGS and tNGS. Also shown are selected amplifications and losses in oncogenes and tumor suppressors, respectively, localized to the chromothriptic chromosomes. Full list is provided in Supplementary Table S7. D, Schematic summary for the rate of major genomic mechanisms detected in the set analyzed by WGS (n = 11) and in the full cohort (n = 20). In the lower diagram, major chromosomes involved by chromothripsis are indicated in the inner doughnut, and corresponding recurrent gene amplifications are indicated in the outer doughnut. E, Total number of SVs identified in samples analyzed by WGS. Variants are color-coded by type. F, Number of fusions predicted in samples with available RNA-seq. G, Diagram illustrating putative enhancer hijacking in case A17 with chromothripsis on chromosome 2 resulting in translocation between SH3RF3 on chromosome 2 and upstream regulatory region of CCND1 on chromosome 11. Epigenetic landscape surrounding the breakpoint was extrapolated from data from multiple tissue types (Epilogos search tool). ChrT, chromothripsis.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Table S1. Integrated genomic and immunohistochemical results for TP53 and RB1 in aSCLC Supplementary Table S2. Demographic, clinicopathologic and immunohistochemical characteristics: Per patient data Supplementary Table S3. Samples and studies performed: Per sample data Supplementary Table S4. Clinicopathologic comparison aSCLC vs other SCLC Supplementary Table S5. MSK-IMPACT metrics and full results for all samples Supplementary Table S6. Full list of SNV by MSK-IMPACT in aSCLC Supplementary Table S7. Full list of CNA by MSK-IMPACT in aSCLC Supplementary Table S8. RB1 and TP53 non-coding variant annotation by WGS Supplementary Table S9. Full list of SV by WGS in aSCLC Supplementary Table S10. Full list of fusions by RNAseq in aSCLC Supplementary Table S11. Timing of amplifications by WGS: mutTimerR Supplementary Table S12. Immunohistochemical antibodies, protocols and scoring criteria Supplementary Table S13. List of covered genes by targeted NGS (MSK-IMPACT assay): somatic and germline.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Table S1. Integrated genomic and immunohistochemical results for TP53 and RB1 in aSCLC Supplementary Table S2. Demographic, clinicopathologic and immunohistochemical characteristics: Per patient data Supplementary Table S3. Samples and studies performed: Per sample data Supplementary Table S4. Clinicopathologic comparison aSCLC vs other SCLC Supplementary Table S5. MSK-IMPACT metrics and full results for all samples Supplementary Table S6. Full list of SNV by MSK-IMPACT in aSCLC Supplementary Table S7. Full list of CNA by MSK-IMPACT in aSCLC Supplementary Table S8. RB1 and TP53 non-coding variant annotation by WGS Supplementary Table S9. Full list of SV by WGS in aSCLC Supplementary Table S10. Full list of fusions by RNAseq in aSCLC Supplementary Table S11. Timing of amplifications by WGS: mutTimerR Supplementary Table S12. Immunohistochemical antibodies, protocols and scoring criteria Supplementary Table S13. List of covered genes by targeted NGS (MSK-IMPACT assay): somatic and germline.